Peer reviewed
Pharmacokinetics and Pharmacodynamics of CJC-1295, a Long-Acting GHRH Analog
Teichman et al. (2006) pharmacokinetic study (PMID 16569233) showing that CJC-1295 increased GH and IGF-1 levels in healthy subjects for up to 6 days after a single dose. The primary published human data for CJC-1295.
Journal of Clinical Endocrinology & Metabolism (PubMed)Published May 1, 2006Accessed Jul 1, 2026
Registry record
Source metadata
- Publisher
- Journal of Clinical Endocrinology & Metabolism (PubMed)
- Source type
- Peer reviewed
- Registry ID
pubmed-cjc1295-pharmacokinetics-2006
Source usage
Linked from 7 pages
Compound
CJC-1295 (no DAC)
CompoundCJC-1295 (with DAC)
ComparisonCJC-1295 + Ipamorelin vs Tesamorelin
ComparisonCJC-1295 DAC vs No DAC
Evidence curationBest Peptides for Growth Hormone Release
GuidePeptide Category Explainers: How Every Compound Class on This Site Is Defined
GuidePeptide Half-Life Reference Table
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.